CN112805066A - 作为pad4抑制剂的经取代的苯并咪唑 - Google Patents

作为pad4抑制剂的经取代的苯并咪唑 Download PDF

Info

Publication number
CN112805066A
CN112805066A CN201980064958.8A CN201980064958A CN112805066A CN 112805066 A CN112805066 A CN 112805066A CN 201980064958 A CN201980064958 A CN 201980064958A CN 112805066 A CN112805066 A CN 112805066A
Authority
CN
China
Prior art keywords
substituted
alkyl
independently
occurrence
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980064958.8A
Other languages
English (en)
Chinese (zh)
Inventor
D·S·加德纳
J·V·德乔亚
J·B·桑特拉
K·恩古
C·安努齐亚托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN112805066A publication Critical patent/CN112805066A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980064958.8A 2018-08-08 2019-08-07 作为pad4抑制剂的经取代的苯并咪唑 Pending CN112805066A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862715858P 2018-08-08 2018-08-08
US62/715,858 2018-08-08
PCT/US2019/045424 WO2020033488A1 (en) 2018-08-08 2019-08-07 Substituted benzimidazoles as pad4 inhibitors

Publications (1)

Publication Number Publication Date
CN112805066A true CN112805066A (zh) 2021-05-14

Family

ID=67766299

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980064958.8A Pending CN112805066A (zh) 2018-08-08 2019-08-07 作为pad4抑制剂的经取代的苯并咪唑

Country Status (18)

Country Link
US (1) US20220402950A1 (cg-RX-API-DMAC10.html)
EP (1) EP3833438B1 (cg-RX-API-DMAC10.html)
JP (1) JP7483678B2 (cg-RX-API-DMAC10.html)
KR (1) KR102825194B1 (cg-RX-API-DMAC10.html)
CN (1) CN112805066A (cg-RX-API-DMAC10.html)
AU (1) AU2019318415A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021002089A2 (cg-RX-API-DMAC10.html)
CA (1) CA3108871A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021000292A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021001219A2 (cg-RX-API-DMAC10.html)
EA (1) EA202190464A1 (cg-RX-API-DMAC10.html)
ES (1) ES2973714T3 (cg-RX-API-DMAC10.html)
IL (1) IL280641A (cg-RX-API-DMAC10.html)
MX (1) MX2021001471A (cg-RX-API-DMAC10.html)
PE (1) PE20211067A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202101176YA (cg-RX-API-DMAC10.html)
TW (1) TW202019411A (cg-RX-API-DMAC10.html)
WO (1) WO2020033488A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566916A (zh) * 2018-08-08 2021-03-26 百时美施贵宝公司 作为pad4抑制剂的经取代的噻吩并吡咯

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3833440A1 (en) 2018-08-08 2021-06-16 Bristol-Myers Squibb Company Indole and azaindole inhibitors of pad enzymes
ES2956090T3 (es) 2018-08-08 2023-12-13 Bristol Myers Squibb Co Inhibidores de bencimidazol de enzimas PAD
CN115298175B (zh) 2020-02-06 2024-05-07 百时美施贵宝公司 可用作免疫抑制剂的大环pad4抑制剂
TW202140477A (zh) 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
MX2022013615A (es) 2020-04-30 2022-11-16 Gilead Sciences Inc Inhibidores de macrociclo de peptidilarginina deiminasas.
EP4267562A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
TW202233174A (zh) 2020-12-22 2022-09-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
CN116492462B (zh) * 2023-02-03 2023-09-22 山东第一医科大学附属眼科医院(山东省眼科医院) Pad4抑制剂在防治角膜移植术后免疫排斥反应中的应用
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104470919A (zh) * 2012-07-26 2015-03-25 葛兰素集团有限公司 作为pad4抑制剂的2-(氮杂吲哚-2-基)苯并咪唑
WO2017100594A1 (en) * 2015-12-09 2017-06-15 Padlock Therapeutics, Inc. Bicyclic inhibitors of pad4
WO2017100601A1 (en) * 2015-12-09 2017-06-15 Padlock Therapeutics, Inc. Aza-benzimidazole inhibitors of pad4
WO2018022897A1 (en) * 2016-07-27 2018-02-01 Padlock Therapeutics, Inc. Covalent inhibitors of pad4
CN107849015A (zh) * 2015-05-21 2018-03-27 葛兰素知识产权发展有限公司 作为pad4抑制剂的苯并咪唑衍生物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104470919A (zh) * 2012-07-26 2015-03-25 葛兰素集团有限公司 作为pad4抑制剂的2-(氮杂吲哚-2-基)苯并咪唑
CN107849015A (zh) * 2015-05-21 2018-03-27 葛兰素知识产权发展有限公司 作为pad4抑制剂的苯并咪唑衍生物
WO2017100594A1 (en) * 2015-12-09 2017-06-15 Padlock Therapeutics, Inc. Bicyclic inhibitors of pad4
WO2017100601A1 (en) * 2015-12-09 2017-06-15 Padlock Therapeutics, Inc. Aza-benzimidazole inhibitors of pad4
WO2018022897A1 (en) * 2016-07-27 2018-02-01 Padlock Therapeutics, Inc. Covalent inhibitors of pad4

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566916A (zh) * 2018-08-08 2021-03-26 百时美施贵宝公司 作为pad4抑制剂的经取代的噻吩并吡咯
KR20210042935A (ko) * 2018-08-08 2021-04-20 브리스톨-마이어스 스큅 컴퍼니 Pad4 억제제로서의 치환된 티에노피롤
CN112566916B (zh) * 2018-08-08 2023-10-20 百时美施贵宝公司 作为pad4抑制剂的经取代的噻吩并吡咯
KR102851932B1 (ko) 2018-08-08 2025-08-27 브리스톨-마이어스 스큅 컴퍼니 Pad4 억제제로서의 치환된 티에노피롤

Also Published As

Publication number Publication date
CL2021000292A1 (es) 2021-06-11
IL280641A (en) 2021-03-25
BR112021002089A2 (pt) 2021-05-04
MX2021001471A (es) 2021-04-28
CO2021001219A2 (es) 2021-02-17
AU2019318415A1 (en) 2021-03-25
SG11202101176YA (en) 2021-03-30
WO2020033488A1 (en) 2020-02-13
US20220402950A1 (en) 2022-12-22
EP3833438B1 (en) 2024-02-07
JP7483678B2 (ja) 2024-05-15
PE20211067A1 (es) 2021-06-09
JP2021534097A (ja) 2021-12-09
KR20210042932A (ko) 2021-04-20
ES2973714T3 (es) 2024-06-24
KR102825194B1 (ko) 2025-06-24
EP3833438A1 (en) 2021-06-16
TW202019411A (zh) 2020-06-01
EA202190464A1 (ru) 2021-06-16
CA3108871A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
CN112566916B (zh) 作为pad4抑制剂的经取代的噻吩并吡咯
KR102825194B1 (ko) Pad4 억제제로서의 치환된 벤즈이미다졸
CN112789087B (zh) Pad酶的苯并咪唑抑制剂
CN112805067B (zh) Pad酶的吲哚及氮杂吲哚抑制剂
JP7163379B2 (ja) Il-17調節剤としてのスピロ環インドリン
CN115298175B (zh) 可用作免疫抑制剂的大环pad4抑制剂
WO2021170627A1 (en) Difluorocyclohexyl derivatives as il-17 modulators
KR101228378B1 (ko) 류코트리엔 α4 하이드롤레이즈의 조정제로서의 티아졸로피리딘-2-일옥시-페닐 및 티아졸로피라진-2-일옥시-페닐 아민
TW202024072A (zh) 作為PI3Kβ抑制劑的1,5-二氮雜萘-4(1H)-酮衍生物
WO2025155786A1 (en) Bicyclic tyrosine kinase 2 inhibitors and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination